<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03103971</url>
  </required_header>
  <id_info>
    <org_study_id>9364</org_study_id>
    <secondary_id>NCI-2017-00421</secondary_id>
    <secondary_id>9364</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <secondary_id>RG9217000</secondary_id>
    <nct_id>NCT03103971</nct_id>
  </id_info>
  <brief_title>huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia</brief_title>
  <official_title>A Two-Stage Phase 1 Open-Label Study of huJCAR014, CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells Bearing a Human Binding Domain, in Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and Acute Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Juno Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial studies the side effects of huJCAR014 in treating patients with relapsed&#xD;
      or refractory B-cell non-Hodgkin lymphoma or acute lymphoblastic leukemia. huJCAR014 CAR-T&#xD;
      cells are made in the laboratory by genetically modifying a patient's T cells and may&#xD;
      specifically kill cancer cells that have a molecule CD19 on their surfaces.&#xD;
&#xD;
      In Stage 1, dose-finding studies will be conducted in 3 cohorts:&#xD;
&#xD;
        1. Aggressive B cell NHL&#xD;
&#xD;
        2. Low burden ALL&#xD;
&#xD;
        3. High burden ALL&#xD;
&#xD;
      In Stage 2, studies may be conducted in one or more cohorts to collect further safety, PK,&#xD;
      and efficacy information at the huJCAR014 dose level(s) selected in Stage 1 for the&#xD;
      applicable cohort(s). There are two separate cohorts for stage 2:&#xD;
&#xD;
        1. Cohort 2A, CAR-na√Øve (n=10): patients who have never received CD19 CAR-T cell therapy.&#xD;
&#xD;
        2. Cohort 2B, CAR-exposed (n=27): patients who have previously failed CD19 CAR-T cell&#xD;
           therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To evaluate preliminary safety of autologous human anti-CD19 chimeric antigen receptor&#xD;
      (CAR)-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes (huJCAR014) in adult patients&#xD;
      with CD19+ relapsed or refractory (R/R) aggressive B-cell non-Hodgkin lymphoma (NHL) and&#xD;
      acute lymphoblastic leukemia (ALL).&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To characterize the pharmacokinetic (PK) profile of huJCAR014 in CD19+ R/R aggressive&#xD;
      B-cell NHL and ALL.&#xD;
&#xD;
      II. To assess the antitumor activity of huJCAR014 in CD19+ R/R aggressive NHL and ALL.&#xD;
&#xD;
      III. To estimate the progression free survival (PFS) and overall survival (OS) in patients&#xD;
      with CD19+ R/R aggressive NHL and ALL treated with huJCAR014.&#xD;
&#xD;
      EXPLORATORY OBJECTIVES:&#xD;
&#xD;
      I. To assess the cellular and humoral immune responses to huJCAR014. II. To assess the&#xD;
      pharmacodynamic effects of huJCAR014. III. To assess the effect of huJCAR014 product&#xD;
      attributes on safety, PK, and antitumor activity.&#xD;
&#xD;
      IV. To assess the effect of tumor and tumor microenvironment on huJCAR014 PK and biomarkers.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of huJCAR014.&#xD;
&#xD;
      Patients undergo leukapheresis. Beginning 1-2 weeks after leukapheresis, patients undergo&#xD;
      lymphodepleting chemotherapy comprising either cyclophosphamide intravenously (IV) daily for&#xD;
      1 day and fludarabine IV daily for 3 days or cyclophosphamide and fludarabine IV daily for 3&#xD;
      days. Within 36-96 hours after completion of lymphodepleting chemotherapy, patients receive&#xD;
      huJCAR014 IV over 20-30 minutes on day 0.&#xD;
&#xD;
      After completion of study treatment, patients are followed up every 30 days for the first 3&#xD;
      months, every 3 months for up to 12 months, and then yearly for 15 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 3, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of toxicity</measure>
    <time_frame>Up to 30 days after the final dose of study therapy</time_frame>
    <description>Will be graded using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. All adverse events (AEs) will be listed and summarized. Summaries of laboratory data will include, at a minimum, treatment-emergent laboratory abnormalities. Summaries of AEs and laboratory abnormalities will be based on the All Treated analysis set.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-limiting toxicity (DLT) rates</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Observed DLT rates will be summarized based on the DLT-Evaluable analysis set. Final DLT rates at each dose level will be estimated by isotonic regression.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum concentration (Cmax) of autologous human anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes (huJCAR014) cells in blood</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>huJCAR014 will be measured in blood using quantitative polymerase chain reaction (PCR) (qPCR) and flow cytometry over 28 days after huJCAR014 infusion. Cmax is the peak concentration of huJCAR014 cells in blood in the first 28 days after infusion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to maximum concentration (Tmax), of huJCAR014 cells in blood</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>huJCAR014 will be measured in blood using quantitative PCR (qPCR) and flow cytometry over 28 days after huJCAR014 infusion. Tmax is the time to reach the maximum concentration of huJCAR014 cells in blood in the first 28 days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve of huJCAR014 cells in blood</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>huJCAR014 will be measured in blood using quantitative PCR (qPCR) and flow cytometry over 28 days after huJCAR014 infusion. AUC is the calculated area under the curve of huJCAR014 concentrations in blood by time after infusion through 28 days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Presence of huJCAR014 cells in bone marrow</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>The persistence of huJCAR014 in the bone marrow at 28 days will be assessed, based on both a qPCR assay and flow cytometry.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete response (CR) rate</measure>
    <time_frame>Up to 15 years</time_frame>
    <description>Will be summarized along with the 2-sided 95% exact Clopper-Pearson confidence intervals based on the efficacy-evaluable (EE) analysis sets. In addition, CR rate will be presented based on the all-treated analysis set</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial response (PR) rate</measure>
    <time_frame>Up to 15 years</time_frame>
    <description>Will be summarized along with the 2-sided 95% exact Clopper-Pearson confidence intervals based on the EE analysis sets.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>Up to 15 years</time_frame>
    <description>Will be defined as the proportion of patients with a best response of either CR or PR. Will be summarized along with the 2-sided 95% exact Clopper-Pearson confidence intervals based on the EE analysis sets. In addition, ORR will be presented based on the All-Treated analysis set.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>Up to 15 years</time_frame>
    <description>Will be defined as the time from date of first response to relapse/progression or death. Kaplan-Meier (KM) methodology will be used to analyze DOR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>From date of first huJCAR014 infusion to progressive disease or death, assessed up to 15 years</time_frame>
    <description>KM methodology will be used to analyze PFS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival (EFS)</measure>
    <time_frame>From the date of the first huJCAR014 infusion to death from any cause, relapse, or treatment failure, whichever occurs first, assessed up to 15 years</time_frame>
    <description>KM methodology will be used to analyze EFS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From date of first huJCAR014 infusion to death, assessed up to 15 years</time_frame>
    <description>KM methodology will be used to analyze OS.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Cellular immune responses to huJCAR014</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Percentage of patients with cellular immune responses to huJCAR014.</description>
  </other_outcome>
  <other_outcome>
    <measure>B-cell depletion in circulation</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Percentage of patients with B cells &lt; 0.01% in blood.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cytokine profile</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Peak concentration of IL-6 in blood after CAR-T cell infusion.</description>
  </other_outcome>
  <other_outcome>
    <measure>CD19 expression on tumor cells in biopsies</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Percentage of patients with CD19-negative disease after CAR-T cell infusion.</description>
  </other_outcome>
  <other_outcome>
    <measure>Phenotype of CAR T cells in blood</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Percentage of patients with CAR-T cells expressing CD62L.</description>
  </other_outcome>
  <other_outcome>
    <measure>Product attributes (e.g., cell phenotype, cytokine profiles)</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Product attributes (e.g., cell phenotype, cytokine profiles) will be correlated with AEs, pharmacokinetic (PK), and tumor response rates.</description>
  </other_outcome>
  <other_outcome>
    <measure>Tumor attributes (e.g., checkpoint expression)</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Tumor attributes (e.g., checkpoint expression) on PK will be correlated with biomarkers (e.g., peripheral cytokines).</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Recurrent Adult Acute Lymphoblastic Leukemia</condition>
  <condition>Recurrent B-Cell Non-Hodgkin Lymphoma</condition>
  <condition>Recurrent Diffuse Large B-Cell Lymphoma</condition>
  <condition>Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma</condition>
  <condition>Refractory Adult Acute Lymphoblastic Leukemia</condition>
  <condition>Refractory B-Cell Non-Hodgkin Lymphoma</condition>
  <condition>Refractory Diffuse Large B-Cell Lymphoma</condition>
  <condition>Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma</condition>
  <condition>Recurrent Transformed Non-Hodgkin Lymphoma</condition>
  <condition>Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements</condition>
  <condition>Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements</condition>
  <condition>Recurrent B Acute Lymphoblastic Leukemia</condition>
  <condition>Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified</condition>
  <condition>Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements</condition>
  <condition>Refractory B Acute Lymphoblastic Leukemia</condition>
  <condition>Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified</condition>
  <condition>Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements</condition>
  <arm_group>
    <arm_group_label>Treatment (leukapheresis, chemotherapy, huJCAR014)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo leukapheresis. Beginning 14-16 days after leukapheresis, patients undergo lymphodepleting chemotherapy comprising either cyclophosphamide IV daily for 1 day and fludarabine IV daily for 3 days or cyclophosphamide and fludarabine IV daily for 3 days. Within 36-96 hours after completion of lymphodepleting chemotherapy, patients receive huJCAR014 IV over 20-30 minutes on day 0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (leukapheresis, chemotherapy, huJCAR014)</arm_group_label>
    <other_name>Anti-CD19-CAR Genetically Engineered Autologous T Lymphocytes huJCAR014</other_name>
    <other_name>Anti-CD19-CAR Genetically Engineered Autologous T-lymphocytes huJCAR014</other_name>
    <other_name>Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes</other_name>
    <other_name>huJCAR014</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (leukapheresis, chemotherapy, huJCAR014)</arm_group_label>
    <other_name>(-)-Cyclophosphamide</other_name>
    <other_name>2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate</other_name>
    <other_name>Carloxan</other_name>
    <other_name>Ciclofosfamida</other_name>
    <other_name>Ciclofosfamide</other_name>
    <other_name>Cicloxal</other_name>
    <other_name>Clafen</other_name>
    <other_name>Claphene</other_name>
    <other_name>CP monohydrate</other_name>
    <other_name>CTX</other_name>
    <other_name>CYCLO-cell</other_name>
    <other_name>Cycloblastin</other_name>
    <other_name>Cycloblastine</other_name>
    <other_name>Cyclophospham</other_name>
    <other_name>Cyclophosphamid monohydrate</other_name>
    <other_name>Cyclophosphamidum</other_name>
    <other_name>Cyclophosphan</other_name>
    <other_name>Cyclophosphane</other_name>
    <other_name>Cyclophosphanum</other_name>
    <other_name>Cyclostin</other_name>
    <other_name>Cyclostine</other_name>
    <other_name>Cytophosphan</other_name>
    <other_name>Cytophosphane</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Fosfaseron</other_name>
    <other_name>Genoxal</other_name>
    <other_name>Genuxal</other_name>
    <other_name>Ledoxina</other_name>
    <other_name>Mitoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Revimmune</other_name>
    <other_name>Syklofosfamid</other_name>
    <other_name>WR- 138719</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (leukapheresis, chemotherapy, huJCAR014)</arm_group_label>
    <other_name>Fluradosa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (leukapheresis, chemotherapy, huJCAR014)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Leukapheresis</intervention_name>
    <description>Undergo leukapheresis</description>
    <arm_group_label>Treatment (leukapheresis, chemotherapy, huJCAR014)</arm_group_label>
    <other_name>Leukocytopheresis</other_name>
    <other_name>Therapeutic Leukopheresis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacological Study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (leukapheresis, chemotherapy, huJCAR014)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        CRITERIA FOR SCREENING&#xD;
&#xD;
          -  Diagnosis of R/R B-cell NHL or ALL as defined below:&#xD;
&#xD;
               -  Relapsed or refractory B-cell NHL meeting all of the following criteria:&#xD;
&#xD;
                    -  Diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS); high&#xD;
                       grade B cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements; LBCL&#xD;
                       transformed from any indolent histology; or primary mediastinal B-cell&#xD;
                       lymphoma (PMBCL)&#xD;
&#xD;
                    -  Prior treatment with an anthracycline and rituximab or another CD20-targeted&#xD;
                       agent (unless the disease is CD20-negative); transformed DLBCL (tDLBCL) must&#xD;
                       have failed treatment for DLBCL&#xD;
&#xD;
                    -  At least one of the following:&#xD;
&#xD;
                         -  Refractory disease after frontline chemo-immunotherapy&#xD;
&#xD;
                         -  Not eligible for autologous hematopoietic stem cell transplant&#xD;
                            (auto-HSCT)&#xD;
&#xD;
                         -  Relapsed or refractory disease after at least 2 lines of therapy or&#xD;
                            after auto-HSCT&#xD;
&#xD;
                         -  Relapsed or refractory disease after allogeneic hematopoietic stem cell&#xD;
                            transplant (allo-HSCT)&#xD;
&#xD;
               -  Relapsed or refractory B-cell ALL (patients with Burkitt's lymphoma/leukemia are&#xD;
                  not eligible)&#xD;
&#xD;
               -  All B-ALL patients must have detectable disease by morphology, flow cytometry,&#xD;
                  cytogenetic analysis (e.g. polymerase chain reaction [PCR], fluorescence in situ&#xD;
                  hybridization [FISH], karyotyping) or imaging (e.g. positron emission tomography&#xD;
                  [PET]/computed tomography [CT]) or a high likelihood of active disease&#xD;
&#xD;
                    -  Refractory: failure to achieve complete response (CR) (minimal residual&#xD;
                       disease [MRD]-negative) at the end of induction&#xD;
&#xD;
                    -  Relapsed: recurrence of disease after achieving CR&#xD;
&#xD;
          -  Evidence of CD19 expression by immunohistochemistry or flow cytometry on any prior or&#xD;
             current tumor specimen or high likelihood of CD19 expression based on disease&#xD;
             histology&#xD;
&#xD;
        CRITERIA FOR LEUKAPHERESIS AND PRE-THERAPY EVALUATION&#xD;
&#xD;
          -  Screening evaluation appropriate for leukapheresis and T-cell collection&#xD;
&#xD;
          -  Adequate vascular access available or planned for leukapheresis procedure (either&#xD;
             peripheral line or surgically placed line)&#xD;
&#xD;
          -  Documentation of CD19 expression on any prior or current tumor biopsy; patients who&#xD;
             have received previous CD19-targeted therapy must have CD19-positive disease confirmed&#xD;
             on a biopsy since completing the prior CD19-targeted therapy&#xD;
&#xD;
          -  Internal review of histology&#xD;
&#xD;
          -  Stage 2; cohort 2B (CAR-exposed) only:&#xD;
&#xD;
               -  Relapsed disease after achieving CR in response to prior CD19-targeted&#xD;
                  nonhuJCAR014 CAR T-cell therapy OR&#xD;
&#xD;
               -  Persistent disease after achieving PR to prior CD19-targeted non-huJCAR014 CAR&#xD;
                  T-cell therapy. Patients who are less than 3 months from prior CD19-targeted&#xD;
                  non-huJCAR014 CAR T-cell therapy must have persistent disease on biopsy or&#xD;
                  imaging (e.g. PET-CT or CT) evidence of disease progression&#xD;
&#xD;
        CRITERIA FOR LYMPHODEPLETING CHEMOTHERAPY AND huJCAR014 TREATMENT&#xD;
&#xD;
          -  Successful collection of T cells for huJCAR014 manufacturing&#xD;
&#xD;
          -  Detectable disease by imaging (for example PET +/- CT, magnetic resonance imaging&#xD;
             [MRI]) and/or pathology evaluation&#xD;
&#xD;
          -  Karnofsky performance status &gt;= 60%&#xD;
&#xD;
          -  Assessed by the investigator to have adequate bone marrow function to receive&#xD;
             lymphodepleting conditioning chemotherapy&#xD;
&#xD;
          -  Serum creatinine =&lt; 1.5 x age-adjusted upper limit of normal (ULN) or calculated&#xD;
             creatinine clearance (Cockcroft and Gault) &gt; 30 mL/min/1.73 m^2&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =&lt; 5 x ULN and&#xD;
             total bilirubin &lt; 2.0 mg/dL unless due to malignancy or Gilbert's syndrome in the&#xD;
             opinion of the principal investigator (PI) or designee&#xD;
&#xD;
          -  Common Terminology Criteria for Adverse Events (CTCAE) grade =&lt; 1 dyspnea and oxygen&#xD;
             saturation (SaO2) &gt;= 92% on room air&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) &gt;= 40% as assessed by echocardiogram (ECHO)&#xD;
             or multiple uptake gated acquisition (MUGA) scan performed within 1 month before&#xD;
             starting lymphodepleting chemotherapy&#xD;
&#xD;
          -  Women of childbearing potential (defined as all women physiologically capable of&#xD;
             becoming pregnant) must agree to both of the following:&#xD;
&#xD;
               -  Use highly effective methods of contraception for at least 6 months after the&#xD;
                  last dose of huJCAR014, and&#xD;
&#xD;
               -  Have a negative serum pregnancy test performed within 28 days before starting&#xD;
                  lymphodepleting chemotherapy&#xD;
&#xD;
          -  Males who have partners of childbearing potential must agree to use an effective&#xD;
             barrier contraceptive method for at least 6 months after the last dose of huJCAR014&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        CRITERIA FOR SCREENING&#xD;
&#xD;
          -  For patients in stage 1 only, prior treatment with any CD19 CAR T-cell therapy is&#xD;
             excluded&#xD;
&#xD;
          -  Known active hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  Any known contraindication to leukapheresis&#xD;
&#xD;
          -  Any known and irreversible contraindication to huJCAR014 therapy&#xD;
&#xD;
          -  Medical, psychological, familial, sociological, or geographical condition that does&#xD;
             not permit compliance with the protocol as judged by the PI or designee, or&#xD;
             unwillingness or inability to follow protocol procedures&#xD;
&#xD;
        CRITERIA FOR LEUKAPHERESIS AND PRE-THERAPY EVALUATION&#xD;
&#xD;
          -  History or presence of clinically relevant central nervous system (CNS) pathology&#xD;
             that, in the opinion of the PI or designee, is a contraindication to lymphodepleting&#xD;
             chemotherapy or huJCAR014 infusion&#xD;
&#xD;
          -  History of another primary malignancy that has not been in remission for at least 2&#xD;
             years with the following exceptions: nonmelanoma skin cancer, curatively treated&#xD;
             localized prostate cancer, cervical carcinoma in situ on biopsy or a squamous&#xD;
             intraepithelial lesion on Pap smear, or other malignancy considered by the&#xD;
             investigator to have a low risk of relapse or progression&#xD;
&#xD;
          -  Active autoimmune disease requiring immunosuppressive therapy, unless considered by&#xD;
             the PI or designee to be eligible&#xD;
&#xD;
          -  Presence of active acute or chronic graft versus host disease (GVHD)&#xD;
&#xD;
          -  Use of any of the following:&#xD;
&#xD;
               -  Cytotoxic or lymphotoxic agents (including prednisone &gt; 5 mg/day or equivalent&#xD;
                  corticosteroid) within 1 week prior to leukapheresis; physiologic corticosteroid&#xD;
                  replacement, and topical or inhaled corticosteroids are not excluded&#xD;
&#xD;
               -  GVHD therapies within 4 weeks prior to leukapheresis (e.g., calcineurin&#xD;
                  inhibitors, methotrexate or other chemotherapeutics, mycophenolate, rapamycin,&#xD;
                  thalidomide, immunosuppressive antibodies such as anti-TNF, anti-IL-6, or&#xD;
                  anti-IL-6R)&#xD;
&#xD;
               -  Experimental agents within 4 weeks prior to leukapheresis unless progression is&#xD;
                  documented on therapy and at least 3 half-lives have elapsed prior to&#xD;
                  leukapheresis&#xD;
&#xD;
               -  Radiation encompassing all sites of known tumor within 6 weeks prior to&#xD;
                  leukapheresis, unless there is evidence of active disease after radiation by&#xD;
                  imaging, biopsy or clinical evaluation&#xD;
&#xD;
               -  Allo-HSCT within 60 days prior to leukapheresis or donor lymphocyte infusion&#xD;
                  (DLI) within 6 weeks prior to leukapheresis&#xD;
&#xD;
               -  Treatment with cladribine within 3 months prior to leukapheresis&#xD;
&#xD;
               -  Treatment with alemtuzumab within 3 months prior to leukapheresis&#xD;
&#xD;
        CRITERIA FOR LYMPHODEPLETING CHEMOTHERAPY AND huJCAR014 TREATMENT&#xD;
&#xD;
          -  Uncontrolled and serious infection&#xD;
&#xD;
          -  Presence of active acute or chronic GVHD&#xD;
&#xD;
          -  DLI within 6 weeks prior to lymphodepletion chemotherapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jordan Gauthier</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>SCCA Immunotherapy Intake</last_name>
    <phone>206-606-4668</phone>
    <email>immunotherapy@seattlecca.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>SCCA Immunotherapy Intake</last_name>
    <phone>855-557-0555</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SCCA Immunotherapy Intake</last_name>
      <phone>206-606-4668</phone>
      <email>immunotherapy@seattlecca.org</email>
    </contact>
    <contact_backup>
      <last_name>SCCA Immunotherapy Intake</last_name>
      <phone>855-557-0555</phone>
    </contact_backup>
    <investigator>
      <last_name>Jordan Gauthier</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 27, 2017</study_first_submitted>
  <study_first_submitted_qc>March 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 7, 2017</study_first_posted>
  <last_update_submitted>September 8, 2021</last_update_submitted>
  <last_update_submitted_qc>September 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

